Harbour Antibodies BV, a Rotterdam, The Netherlands, and Cambridge, MA-based creator of transgenic mice to aid in the discovery of new human antibody-based therapies, raised €2.5M ($3.3M) in funding.
The round was led by Atlas Venture. In conjunction with the funding, Atlas Venture’s Peter Barrett will join the Board of Directors as Chairman.
The company intends to use the funds to continue R&D and commercialize its technologies.
Established in 2006 by Professor Frank Grosveld, PhD, CSO, and Chair of the Department of Cell Biology at Erasmus Medical Center, Rotterdam and led by newly appointed pharma executive BJ Bormann, Ph.D., as CEO, Harbour Antibodies uses transgenic mouse technology to produce high affinity human antibodies.
The company has developed two types of human immunoglobulin gene transgenic mice:
– mice that generate “conventional” tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and
– mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs).
Both Harbour transgenic mouse lines are now available to licensing partners.